The present invention includes novel retinoid compounds that have
selectivity as RXR agonists on one or more isoforms of RXR, currently,
RXR.alpha., RXR.beta., or RXR.gamma.. The present compounds, and
pharmaceutical compositions incorporating these compounds, therefore, are
effective in treating conditions mediated by RXRs. Among other
physiological responses, the compounds of the present invention reduce
blood glucose and maintain body weight, and, thus, are useful for the
treatment of diabetes (NIDDIM) and obesity.